Free Newsletter
Pfizer provides top post for vax scientist
Now that Pfizer is reordering its house to make way for the $68 billion addition of Wyeth, it has taken particular pains to retain the skills of Wyeth's head of vaccines, Emilio Emini (photo). Emini made the shift to Wyeth after blazing a path in vaccines for Merck, where he helped lead the development of new vaccines for shingles, cancer-causing viruses and severe diarrhea.
In the newly restructured R&D organization at Pfizer, which is being split between small and large molecule development, Emini is being given the title of chief scientific officer for vaccines. And analysts were quick to note that the top research position is a sign of just how important Pfizer execs view retaining Wyeth's scientific talents.
"You don't want to lose someone who is a driving force behind vaccines, which are a core value driver of the overall Wyeth acquisition," analyst Seamus Fernandez of Leerink Swann tells the Wall Street Journal.
- read the report in the Wall Street Journal
Related Article:
Pfizer names top scientists as it shakes up research
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




